Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as MD-1100 Acetate
MD-1100 · 2 trials · 2 indications
| Name | Type | Description |
|---|---|---|
| MD-1100 Acetate | DRUG | - |
Inclusion Criteria: * Male or non-pregnant, non-breastfeeding female, age 18-70 years old at the time of first dose; * Sexually active patients of childbearing potential agree to use double-barrier birth control; * Females of childbearing potential must complete negative pregnancy tests prior to fi...
MD-1100 is an investigational small molecule developed by Ironwood Pharmaceuticals, Inc. (ticker IRWD) for gastrointestinal conditions. It has been studied in Phase 2 clinical trials for constipation and irritable bowel syndrome. MD-1100 is also known as MD-1100 Acetate.
MD-1100 has been studied for the treatment of constipation and irritable bowel syndrome. Specifically, clinical trials have evaluated it in patients with chronic constipation and in patients with constipation-predominant irritable bowel syndrome (C-IBS). It is an investigational therapy and has not been approved for any indication.
MD-1100 is being developed by Ironwood Pharmaceuticals, Inc., which trades on the Nasdaq under the ticker symbol IRWD. Ironwood is a gastrointestinal-focused biopharmaceutical company.
MD-1100 is in Phase 2 clinical development. It has completed Phase 2 trials for constipation and irritable bowel syndrome. No Phase 3 trials have been reported, and the drug remains investigational.
MD-1100 has been evaluated in two completed Phase 2 trials: NCT00306748, which studied MD-1100 Acetate administered for 14 days in 40 patients with chronic constipation, and NCT00258193, which studied MD-1100 Acetate's effect on gastrointestinal transit in 36 patients with constipation-predominant irritable bowel syndrome. Both trials were conducted in the United States.
Yes, MD-1100 Acetate is an alternative name for MD-1100. The two names refer to the same investigational drug candidate. Clinical trial records for MD-1100 use the acetate form designation.